I blogged the European Union approved a long acting injectable med for HIV based on cabotegravir & rilpivirine. The injection, Cabenuva is given monthly. An oral regimen will proceed it for a month & is marketed as, Vocabria. ViiV Healthcare is researching how to extend the time between injections. The FDA recently approved this med.
Taken from the piece.
The most common adverse reactions ... were injection site reactions, fever (pyrexia), fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness and rash.
I'll try to keep up with this. Take care
Cya...
No comments:
Post a Comment